Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study
British Journal of Dermatology · 17.04.2026 · 194 (5) · 971-973
DOI: 10.1093/bjd/ljaf519 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 26.12.2025. Verfasst von John E Harris und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Mass General Brigham, Boston, MA, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Incyte Corporation.
Abstract (Originalsprache)
We present data from the TRuE-V1/TRuE-V2 rollover TRuE-V long-term extension study evaluating withdrawal and continuation of ruxolitinib cream treatment. Among patients with near-complete facial repigmentation in TRuE-V1/TRuE-V2, approximately 70% of those randomized to treatment continuation and approximately 40% of those randomized to treatment withdrawal maintained facial repigmentation indicative of treatment success (i.e. ≥ F-VASI 75). Lost repigmentation could be regained in a timely manner following reinitiation of open-label active treatment.
Autor:innen und Institutionen
- Department of Dermatology, Mass General Brigham, Boston, MA, USA.
ORCID-Profile: Kim Papp, Thierry Passeron
Förderung
- Incyte Corporation
Zitieren
APA
Harris, J. E., Papp, K., Ezzedine, K., Sebastian, M., Pandya, A. G., Seneschal, J., Amster, M., Shayesteh Alam, M., Forman, S. B., Zdybski, J., Nuara, A., Kornacki, D., Wei, S., Passeron, T., & Rosmarin, D. (2026). Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study. British Journal of Dermatology, 194(5), 971-973. https://doi.org/10.1093/bjd/ljaf519
Vancouver
Harris JE, Papp K, Ezzedine K, Sebastian M, Pandya AG, Seneschal J, et al. Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study. British Journal of Dermatology. 2026;194(5):971-973. doi:10.1093/bjd/ljaf519
BibTeX
@article{Harris2026,
author = {Harris, John E and Papp, Kim and Ezzedine, Khaled and Sebastian, Michael and Pandya, Amit G and Seneschal, Julien and Amster, Mark and Shayesteh Alam, Maryam and Forman, Seth B and Zdybski, Jacek and Nuara, Anthony and Kornacki, Deanna and Wei, Shaoceng and Passeron, Thierry and Rosmarin, David},
title = {Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study},
journal = {British Journal of Dermatology},
year = {2026},
volume = {194},
number = {5},
pages = {971--973},
doi = {10.1093/bjd/ljaf519}
}
EUVIMED